Planet MicroCap Podcast | MicroCap Investing Strategies

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF): Specialty Pharmaceuticals Focused on Dermatology Products

Aug 21, 2024

Craig Mull, CEO of Cipher Pharmaceuticals, and Bryan Jacobs, President, delve into the company’s strategic focus on dermatology. They discuss their impressive acquisition of Natroba, reshaping their product lineup for younger audiences. Listeners learn about ongoing clinical trials for nail fungus treatments, challenges in the competitive landscape, and operational synergies post-acquisition. The pair outlines their ambitious 3-5 year vision, emphasizing innovation and market expansion in specialty pharmaceuticals. This engaging conversation reveals the future of dermatological care.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

ANECDOTE

Cipher's Origins and Refocusing

Cipher Pharmaceuticals was founded in 2004 within CML Healthcare, a family business involved in diagnostic lab and imaging services.
Craig Mull, current CEO, was the first CEO and returned in 2020 to refocus the company on dermatology and profitability.

INSIGHT

Dermatology Focus

Cipher Pharmaceuticals chose to focus on dermatology in 2020 due to their existing acne product and opportunistic reasons.
This focus allowed them to leverage their experience and target a specific market.

INSIGHT

Natroba Acquisition

Cipher Pharmaceuticals acquired Natroba's product rights and US commercial sales team for $89.5 million.
This acquisition aligned with Cipher's focus on profitability and offered growth potential.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

My guests on the show today is Craig Mull (CEO), Bryan Jacobs (President) of Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF). Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America. On July 29, 2024, Cipher announced that it acquired the global product rights for Natroba, as well as the commercial sales team in the US for $89.5 million from ParaPRO. Following this acquisition, the largest in the company's history, I invited on the management team to learn more about:

History of Cipher and how they've narrowed their focus on providing dermatology products for the under-18 consumer
What the competitive landscape looks like
Acquisition of Natroba and what that means moving forward
Phase 3 clinical trial for nail fungus treatment with Moberg Pharma, and;
their 3-5 year vision for the company

For more information about Cipher Pharmaceuticals, please visit: https://www.cipherpharma.com/

This podcast was recorded and is being made available by SNN, Inc. (together with its affiliates and its and their employees, “SNN”) solely for informational purposes. SNN is not providing or undertaking to provide any financial, economic, legal, accounting, tax, or other advice in or by virtue of this podcast. The information, statements, comments, views, and opinions provided in this podcast are general in nature, and such information, statements, comments, views, and opinions, and the viewing of/listening to this podcast are not intended to be and should not be construed as the provision of investment advice by SNN. The information, statements, comments, views, and opinions expressed in this podcast do not constitute and should not be construed as an offer to buy or sell any securities or to make or consider any investment or other course of action.

The information, statements, comments, views, and opinions expressed in this podcast (including by guest speakers who are not officers, employees, or agents of SNN) are not necessarily those of SNN and may not be current. Reference to any specific third-party entity, product, service, materials, or content does not constitute an endorsement or recommendation by the SNN. SNN assumes no responsibility or liability for the accuracy or completeness of the content contained in third party materials or on third party sites referenced in this podcast or the compliance with applicable laws of such materials and/or links referenced herein. The views expressed by guest speakers are their own and their appearance on this podcast does not imply an endorsement of them or any entity they represent. SNN does not make any representation or warranty as to the accuracy or completeness of any of the information, statements, comments, views, or opinions contained in this podcast, which may include forward-looking statements where actual results may differ materially. SNN does not undertake any obligation whatsoever to provide any form of update, amendment, change, or correction to any of the information, statements, comments, views or opinions set forth in this podcast.

SNN EXPRESSLY DISCLAIMS ANY AND ALL LIABILITY OR RESPONSIBILITY FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR OTHER DAMAGES ARISING OUT OF ANY INDIVIDUAL'S USE OF, REFERENCE TO, RELIANCE ON, OR INABILITY TO USE, THIS PODCAST OR THE INFORMATION PRESENTED IN THIS PODCAST.

By accessing this podcast, the listener acknowledges that the entire contents and design of this podcast, are the property of SNN, or used by SNN with permission, and are protected under U.S. and international copyright and trademark laws. Except as otherwise provided herein, users of this podcast may save and use information contained in the podcast only for personal or other non-commercial educational purposes. No other use, including without limitation, reproduction, retransmission, or editing of this podcast may be made without the prior written consent of SNN.